Porsolt Expands Its in Vitro Drug Discovery Service Capabilities With the Acquisition of Fluofarma

Porsolt has acquired Fluofarma, a Bordeaux-based company focused on the provision of cell-based assays and in vitro screening services. The acquisition further expands Porsolt's capabilities and services that can assist clients at earlier stages of their drug discovery programs.

Fluofarma, established in 2003, specializes in providing tailored services in cell biology and high content analysis, an approach highly solicited in association with predictive tools and cell-based models, thereby fulfilling pharmaceutical industry requirements to optimize the drug discovery pipeline. Fluofarma's expertise include in vitro disease models, cell-cell interaction models, assay development, and tissue analysis, all combined with the latest technologies in automated flow cytometry, high content imaging, live imaging, and high content histology. "The acquisition of Fluofarma complements Porsolt's extensive drug discovery portfolio of services and capabilities addressing multiple stages of the drug discovery process", commented Dr Guillaume Froget, President and CEO of Porsolt. "This is an exciting development for Porsolt as we continue to grow to meet the needs of our well established global client base."

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.